ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pimicotinib

Also written as “pimicotinib capsules”, “ABSK021” and “Pimicotinib”.

Its studies are mostly in Giant Cell Tumor of Tendon Sheath · Synovitis, Pigmented Villonodular · Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Drug pagePimicotinib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 13, 202314 company-led studies, 6 open or runningNext primary completion: Aug 22, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Caymanits history only135 open or runningphase 3since Mar 13, 2023Nov 27, 2019Dec 31, 2031phase 1 · NCT04192344
Merck KGaA, Darmstadt, Germany11 open or runningphase 2since Mar 23, 2026Mar 23, 2026Aug 22, 2028phase 2 · NCT07499362

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2023Named pimicotinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ABSK021
  2. Mar 23, 2026First study: phase 2 study in Giant Cell Tumor of Tendon SheathFirst studyNCT07499362 · 20 planned · Japan

Ahead

  1. Aug 22, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathNCT07499362

TargetBeta

CSF1R →read by rule
“An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), ”NCIt, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
axatilimabruleIncytephase 312
vimseltinibruleOno Pharmaceuticalphase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07499362Giant Cell Tumor of Tendon Sheath · Japan2RecruitingAug 22, 202820

How it is read

Names in the registry

  • “pimicotinib capsules”, 4 entries
  • “ABSK021”, 3 entries
  • “Pimicotinib”, 2 entries
  • “Pimicotinib(ABSK021)”, 1 entry
  • “Pimicotinib capsule”, 1 entry

Codes read as this program: ABSK021.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.